Business Context and Reporting Period
This Form 8-K is filed by Manhattan Pharmaceuticals, Inc. (noted as TG THERAPEUTICS, INC. in metadata) for the reporting period ending September 18, 2007. The filing addresses a critical compliance issue regarding the company's continued listing on the American Stock Exchange (AMEX).
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures. However, it explicitly states the following financial conditions triggering the listing review:
- Stockholder's Equity: Less than $4,000,000 (violating Section 1003(a)(ii)) and less than $6,000,000 (violating Section 1003(a)(iii)).
- Profitability: The company reported losses from continuing operations and/or net losses in three out of its four most recent fiscal years, and in its five most recent fiscal years.
Material Changes and Listing Status
On September 18, 2007, the company received notice from the AMEX staff indicating non-compliance with continued listing standards. This follows a history of compliance issues:
- Initial Notice: First received on January 8, 2007.
- Previous Plan: A compliance plan was accepted by AMEX on March 23, 2007, with a target date of April 16, 2008.
- Temporary Compliance: On May 31, 2007, AMEX noted the company had regained compliance but required two consecutive quarters of compliance to close the plan period.
- Current Status: The company failed to demonstrate compliance for two consecutive quarters. Consequently, the plan period remains open until April 16, 2008.
Outlook, Risks, and Management Commentary
Management Action Plan: The company intends to submit a new plan to AMEX by October 18, 2007, detailing actions to regain full compliance by April 16, 2008.
Risks and Contingencies:
- If the company fails to regain compliance by April 16, 2008, or fails to make sufficient progress under the new plan, AMEX may initiate delisting proceedings.
- During the plan period, the company will be subject to periodic reviews to assess progress.
Investor Verification Checklist
- Verify the company's current stockholder's equity and recent net loss figures in the most recent 10-K or 10-Q filings.
- Monitor the submission of the compliance plan to AMEX by the October 18, 2007 deadline.
- Track the company's ability to achieve two consecutive quarters of compliance to avoid delisting.
- Review the attached press release (Exhibit 99.1) for additional details on the company's financial strategy.